Research Keyword: blinding

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

mycolabadmin

This study compared psychedelic drugs (psilocybin, LSD, MDMA, ayahuasca) with the antidepressant escitalopram for treating depression. Researchers analyzed 19 clinical trials and found that while psilocybin showed promise, its actual effectiveness was smaller than previously reported due to blinding issues in earlier studies. High-dose psilocybin performed better than escitalopram in some comparisons, but had a similar small effect size to current antidepressants.

Read More »

Addressing blinding in classic psychedelic studies with innovative active placebos

mycolabadmin

This research paper discusses how scientists can better test whether psychedelic drugs actually work by improving the way they conduct clinical trials. A major problem is that psychedelic drugs produce obvious effects that make it easy for patients and researchers to figure out who received the real drug versus a fake one. The authors recommend using different types of drugs as placebos that produce similar effects without being therapeutic themselves, such as certain existing medications. By using these better-designed placebos along with other strategies, future research can more definitively prove whether psychedelics truly help treat depression, chronic pain, and other conditions.

Read More »

Psychedelic-assisted therapy – supposedly paradigm-shifting research with poor attempts at hypotheses falsifying and questionable ethics

mycolabadmin

This paper critically examines recent clinical trials testing MDMA and psilocybin for treating PTSD and depression. While these trials reported promising results, the author identifies serious scientific and ethical problems: participants could tell whether they received the drug or placebo due to its strong effects, researchers and therapists who strongly believed in the treatment may have unconsciously influenced patient responses, and negative side effects may have been downplayed. The author argues that without fixing these problems, the entire field of psychedelic therapy research could lose credibility.

Read More »
Scroll to Top